FDA-approved Hepatitis B Treatments Adefovir dipivoxil (Hepsera) In Comparison to Adefovir, the Efficacy of Tenofovir Seems Unchanged by the Presence of Lamivudine-resistant HBV - 11/23/05 Experimental HBV Drug Pradefovir: Safety, Tolerability, Antiviral Activity, and Pharmacokinetics - 11/21/05 Five-year Treatment with Adefovir Results in Regression of Liver Fibrosis in Patients with HBeAg-negative Chronic Hepatitis B - 11/16/05 Adefovir Add-on Therapy after Emergence of Lamivudine Resistance Is Effective and Unlikely to Result in Resistance to Adefovir in HIV-HBV Coinfected Patients - 11/16/05 A Cost-Effectiveness Analysis of Treatment Alternatives for Hepatitis B Cirrhosis - 11/16/05 Long-term Treatment with Adefovir Dipivoxil Is More Cost Effective Than Lamivudine for HBeAg-negative Patients with Chronic Hepatitis B - 11/16/05 Effective Treatment Does Not Reach HBV Patients in the Netherlands Due to Lack of Use by Specialists of Treatment Guidelines - 11/16/05 Epivir-HBV (Lamivudine) Histologic Improvement in Patients with Chronic Hepatitis B after Treatment with Peginterferon alfa-2a (Pegasys) Monotherapy - 11/18/05 Maximal Early HBV Suppression is Predictive of Optimal Virologic and Clinical Efficacy in Nucleoside-Treated Hepatitis B Patients: The GLOBE Study - 11/18/05 Adefovir Add-on Therapy after Emergence of Lamivudine Resistance Is Effective and Unlikely to Result in Resistance to Adefovir in HIV-HBV Coinfected Patients - 11/16/05 Long-term Treatment with Adefovir Dipivoxil Is More Cost Effective Than Lamivudine for HBeAg-negative Patients with Chronic Hepatitis B - 11/16/05 Efficacy and Safety of Entecavir and Lamivudine in HBV Patients with Cirrhosis - 11/16/05 Effective Treatment Does Not Reach HBV Patients in the Netherlands Due to Lack of Use by Specialists of Treatment Guidelines - 11/16/05 Entecavir (Baraclude) Entecavir Two-Year Resistance Update - 11/16/05 Efficacy and Safety of Entecavir and Lamivudine in HBV Patients with Cirrhosis - 11/16/05 Effective Treatment Does Not Reach HBV Patients in the Netherlands Due to Lack of Use by Specialists of Treatment Guidelines - 11/16/05 Intron A (interferon alfa-2a) Effective Treatment Does Not Reach HBV Patients in the Netherlands Due to Lack of Use by Specialists of Treatment Guidelines - 11/16/05 Pegasys (peginterferon alfa-2a) Histologic Improvement in Patients with Chronic Hepatitis B after Treatment with Peginterferon alfa-2a (Pegasys) Monotherapy - 11/18/05
<--- Return to the 56th AASLD Main Page
